AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

$2.9 Billion Interventional Oncology Market by Product, Procedures, Cancer - Global Forecast to 2024 - ResearchAndMarkets.com

March 21, 2019

DUBLIN--(BUSINESS WIRE)--Mar 21, 2019--The “Interventional Oncology Market by Product, Procedures, Cancer - Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering.

The global interventional oncology market is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in 2019, at a CAGR of 6.8% from 2019 to 2024.

The growth of this market is primarily driven by the rising preference for minimally invasive procedures, expansion of the target patient population, increasing public-private funding and government support for cancer research, technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research. However, the dearth of well-trained and skilled radiologists and oncologists, high costs of interventional oncology procedures, and unfavorable regulations are expected to limit market growth to a certain extent.

The transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT segment accounted for the largest share of the global interventional oncology market during the forecast period

On the basis of procedure, the interventional oncology market is segmented into thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization TACE, transcatheter arterial radioembolization TARE or selective internal radiation therapy SIRT, and transcatheter arterial embolization TAE or bland embolization procedures. In 2018, the TARE/SIRT procedures segment accounted for the largest share of this market majorly due to the rising prevalence of cancer, increasing demand for minimally invasive procedures, growing adoption of embolization procedures, and the clinical efficacy of Yttrium-90 radioembolic agents which are used in these procedures.

The liver cancer segment accounted for the largest share of the interventional oncology market during the forecast period

Based on cancer type, the interventional oncology market is segmented into liver cancer, lung cancer, kidney cancer, bone cancer, and other cancers. The other cancers segment includes pediatric cancer, prostate cancer, and breast cancer. The liver cancer segment accounted for the largest share in the interventional oncology market in 2018.

Europe accounted for the second-largest share of the global market in 2018

The interventional oncology market is segmented into five major regions, namely North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe accounted for the second-largest share in 2018. The rising incidence of cancer, coupled with the growing geriatric population in Europe, is a key factor propelling the demand for interventional oncology products in this region.

Prominent market players are focusing on improving the quality of patient care across Europe by commercializing advanced products, investing in technological innovations, and partnering with other institutions and organizations for spreading cancer awareness. This is another major factor driving market growth.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Interventional Oncology: Market Overview
4.2 Geographic Analysis: Interventional Oncology Market, By Product
4.3 Asia Pacific: Ablation Devices Market, By Type (2018)
4.4 Europe: Interventional Oncology Market, By Cancer Type (2018)
4.5 Interventional Oncology Market, By Procedure, 2019 vs 2024 (USD Million)
4.6 Geographical Snapshot of the Interventional Oncology Market

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Rising Patient Preference for Minimally Invasive Procedures
5.2.1.2 Expansion of the Target Patient Population
5.2.1.3 Increasing Public-Private Funding and Government Support for Interventional Oncology
5.2.1.4 Technological Advancements in Interventional Oncology
5.2.2 Restraints
5.2.2.1 Dearth of Well-Trained and Skilled Radiologists and Oncologists
5.2.2.2 Unfavorable Regulations
5.2.3 Opportunities
5.2.3.1 Emerging Economies Offer High Growth Potential
5.2.3.2 Rising Awareness About the Benefits of Interventional Oncology
5.2.4 Challenges
5.2.4.1 Limited Clinical Data to Support Therapeutic Efficacy
5.2.4.2 Strong Market Positioning of Alternative Therapies
5.3 Market Trends
5.3.1 Personalized Or Precision Interventional Oncology

6 Interventional Oncology Market, By Product
6.1 Introduction
6.2 Embolization Devices
6.2.1 Interventional Oncology Embolization Devices Market Split, By Procedure
6.2.2 Interventional Oncology Embolization Devices Market Split, By Cancer Type
6.2.3 Radioembolic Agents
6.2.4 Non-Radioactive Embolic Agents
6.3 Ablation Devices
6.3.1 Technological Advancements in Ablation DevicesA Key Driver for Market Growth
6.3.2 Radiofrequency (RF) Ablation Devices
6.3.3 Microwave Ablation Devices
6.3.4 Cryoablation Devices
6.3.5 Other Ablation Devices
6.4 Support Devices
6.4.1 Interventional Oncology Support Devices Market Split, By Procedure
6.4.2 Interventional Oncology Support Devices Market Split, By Cancer Type
6.4.3 Microcatheters
6.4.4 Guidewires
6.4.4.1.1 Guidewires Market Split, By Procedure
6.4.4.1.2 Guidewires Market Split, By Cancer Type

7 Interventional Oncology Market, By Procedure
7.1 Introduction
7.2 Thermal Tumor Ablation
7.2.1 Increasing Clinical Evidence is A Major Factor Driving Market Growth
7.3 Non-Thermal Tumor Ablation
7.3.1 Nanoknife has Emerged as A Potential Alternative to Thermal Tumor Ablation Techniques
7.4 Transcatheter Arterial Chemoembolization
7.4.1 Ability to Treat Small and Large-Sized Tumors - A Major Factor Driving the Demand for Tace Procedures
7.5 Transcatheter Arterial Radioembolization/Selective Internal Radiation Therapy
7.5.1 Tare Shows Greater Clinical Efficacy as Compared to Tace
7.6 Transcatheter Arterial Embolization/Bland Embolization
7.6.1 Increasing Clinical Evidence for Tare and Tace to Restrain Growth of This Market

8 Interventional Oncology Market, By Cancer Type
8.1 Introduction
8.1.1 Liver Cancer
8.1.1.1 Increasing Disease Prevalence and Rising Research Activity are Driving Market Growth
8.1.2 Lung Cancer
8.1.2.1 Increasing Number of Cancer Cases Will Drive the Demand for Interventional Oncology Procedures
8.1.3 Bone Cancer
8.1.3.1 Interventional Oncology Procedures Can Eliminate Tumors Directly and Relieve Pain
8.1.4 Kidney Cancer
8.1.4.1 Interventional Oncology Procedures are Appropriate for Patients With A Genetic Disposition for Multiple Tumors
8.1.5 Other Cancers

9 Interventional Oncology Market, By Region
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 US to Dominate the North American Interventional Oncology Market
9.2.2 Canada
9.2.2.1 Public-Private Initiatives to Support the Adoption of Interventional Oncology Procedures in Canada
9.3 Europe
9.3.1 Germany
9.3.1.1 Germany is the Fastest-Growing Market in Europe
9.3.2 UK
9.3.2.1 Increasing Awareness and Support for Cancer-Related Activities to Drive Market Growth in the UK
9.3.3 France
9.3.3.1 Radiofrequency Ablation Dominated the Ablation Devices Market in France
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Rising Geriatric Population and Universal Healthcare Reimbursement are the Major Driving Factors
9.4.2 China
9.4.2.1 Increasing Cancer Incidence and Growing Patient Population to Drive Market Growth in China
9.4.3 India
9.4.3.1 Improving Research Capabilities Coupled With the Expansion of Key Players to Drive Market Growth in India
9.4.4 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.1.1 Brazil to Account for the Largest Share of the Latin American Interventional Oncology Market
9.5.2 Mexico
9.5.2.1 Growing Awareness Campaigns and Rising Incidence of Cancer to Drive Market Growth in Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Improving Healthcare Infrastructure and Rising Incidence of Cancer are Driving Growth in the Middle East and Africa

10 Competitive Landscape
10.1 Overview
10.2 Global Market Share Analysis, 2017
10.3 Competitive Scenario (2015 - 2019)
10.4 Vendor Dive Overview
10.5 Vendor Inclusion Criteria
10.6 Vendor Dive

11 Company Profiles
11.1 Healthtronics, Inc.
11.2 Trod Medical
11.3 Sanarus Technologies, Inc.
11.4 Teleflex, Inc.
11.5 Imbiotechnologies Ltd.
11.6 Medwaves, Inc.
11.7 Icecure Medical
11.8 Terumo Corporation
11.9 Medtronic PLC
11.10 BTG PLC
11.11 Johnson & Johnson
11.12 Merit Medical Systems, Inc.
11.13 Boston Scientific Corporation
11.14 Angiodynamics, Inc.
11.15 Cook Medical

For more information about this report visit https://www.researchandmarkets.com/research/ftjt93/2_9_billion?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190321005436/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/21/2019 10:00 AM/DISC: 03/21/2019 10:00 AM

http://www.businesswire.com/news/home/20190321005436/en